145,95 €
145,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
73 °P sammeln
145,95 €
145,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
73 °P sammeln
Als Download kaufen
145,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
73 °P sammeln
Jetzt verschenken
145,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
73 °P sammeln
  • Format: PDF

The second volume of the book Emerging Human Viral Diseases discusses pathogenesis, diagnostics, and therapeutic strategies against viral encephalitis, gastroenteritis, and human immunodeficiency viral infections. The chapters discuss symptoms, diagnostics, and preventive strategies against viral infections. The book also reviews the epidemiology and evolution of viruses causing these infections. It also examines symptoms and strategies for developing novel diagnostics and the vaccine against these viruses. Toward the end, it discusses various biosafety principles for handling emerging viruses…mehr

  • Geräte: PC
  • ohne Kopierschutz
  • eBook Hilfe
  • Größe: 32.97MB
Produktbeschreibung
The second volume of the book Emerging Human Viral Diseases discusses pathogenesis, diagnostics, and therapeutic strategies against viral encephalitis, gastroenteritis, and human immunodeficiency viral infections. The chapters discuss symptoms, diagnostics, and preventive strategies against viral infections. The book also reviews the epidemiology and evolution of viruses causing these infections. It also examines symptoms and strategies for developing novel diagnostics and the vaccine against these viruses. Toward the end, it discusses various biosafety principles for handling emerging viruses and reviews various bioinformatics tools and databases in virology research. This timely book offers valuable resource for the scientists working in the field of emerging viral infections and those involved in preventing, controlling, and managing viral diseases.

Inclusively this book will be valuable guide covering most recent scientific progress in emerging human viral diseases and management and will serve as the best resource for undergraduates, graduates, medical professionals, researchers, public health physicians, and national and international health authorities.


Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Autorenporträt
Dr. Prudhvilal Bhukya is a virologist currently serving ICMR-National Animal Resource Facility for Biomedical Research (NARFBR), Hyderabad. He has been involved in preclinical vaccine testing facility activities at NARFBR. His area of working includes preclinical vaccinology studies, host viral interactions studies of emerging human viral infections, and prevention and control of diseases and development of tools to prevent outbreaks. He has done his PhD from ICMR-National Institute of Virology-Pune on human hepatitis B virus. He proved his credentials by working on HAV, HBV, HEV, SARS COV-2, & Japanese encephalitis with his publication record. He has presented his work in numerous national and international conferences. He has proved his accolades with several publications in international journals like Journal of General Virology, Journal of Virology, Journal of Travel Medicine, Indian Journal of Medical Microbiology, and Science of Total Environment. He is a well-experienced manuscript writer and editor and has contributed to several books and chapters as an author for publishers like Springer Nature, CRC-Press, Intech open, IGI Global Publications, etc. His contribution for these books as an editor will act as catalyst as his comments are really critical and an achievement for the book.   Dr. Anbazhagan completed his undergraduate studies at TANUVAS, Tamil Nadu, and obtained his postgraduate degree from ICAR-IVRI, Uttar Pradesh. He has carried out his doctoral research in the field of veterinary microbiology at ICAR-IVRI, UP. During his doctoral studies, he obtained expertise in working with risk group 2 and 3-level zoonotic pathogens. He had experience in the development of genome-edited vaccines for high-risk pathogens. He has expertise in small and large animal experiments for preclinical analysis of viral and bacterial candidate vaccines. He also has proficiency in working with next-generation sequencing for emerging and remerging microbial genome characterization. Along with this, he possess expertise in isolation, characterization, and analysis of several emerging antimicrobial resistance pathogens. Additionally, he conducted molecular docking studies for SARS-CoV-2, identifying therapeutic molecules, and exploring the interaction of SARS-CoV-2 with ACE2 receptors in domestic and wild animals. His multidisciplinary approach displays a comprehensive understanding of veterinary microbiology and one health, contributing significantly to the understanding and development of strategies against infectious agents.